STOCK TITAN
  1. Home
  2. News
  3. SAGE

Sage Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

CAMBRIDGE, Mass.--()--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to announce third quarter 2020 financial results and discuss recent business updates.

The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

Contacts

Investor Contact
Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com

Media Contact
Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com

Stock SAGE logo
Sage Therapeutics, Inc

NASDAQ:SAGE

SAGE Rankings

#2710 Ranked by Market Cap
#4744 Ranked by Stock Gains
N/A Ranked by Dividends

SAGE Latest News

May 7, 2024
Sage Therapeutics to Participate in Upcoming May Investor Conferences
Apr 25, 2024
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Apr 17, 2024
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Apr 11, 2024
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Feb 28, 2024
Sage Therapeutics to Present at Upcoming March Investor Conferences

SAGE Stock Data

721.58M
47.55M
12.56%
95.55%
14.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About SAGE

sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.